Merck击败了Q2收入预测,提高了全年指导,计划到2027年节省3B美元的费用。 Merck beats Q2 earnings forecasts, raises full-year guidance, and plans $3B cost savings by 2027.

Merck & Co.报告了2025年的Q2收入,使分析师的预期受到打击,EPS为2.13美元,尽管其《公认会计原则》的收入为158亿美元,略微错过了预测。 Merck & Co. reported Q2 2025 earnings, beating analyst expectations with an EPS of $2.13, though its GAAP revenue of $15.8 billion slightly missed forecasts. KEYTRUDA销售额猛增9%,共计80亿美元,而GARDASIL销售额下降了55%。 KEYTRUDA sales surged 9%, totaling $8 billion, while GARDASIL sales dropped 55%. Merck提出了其2025年全年指导方针,并宣布了一项多年优化倡议,到2027年节省30亿美元的费用。 Merck raised its full-year 2025 guidance and announced a multiyear optimization initiative for $3 billion in cost savings by 2027. 该公司的市场上限为2 113.3亿美元,红利收益率为3.85%。 The company's market cap is $211.33 billion, with a dividend yield of 3.85%.